Zevra Therapeutics, Inc. ZVRA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s financing cash flow?
- Zevra Therapeutics, Inc. (ZVRA) reported financing cash flow of -$52.8M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Zevra Therapeutics, Inc.'s financing cash flow decreased by 3385.9% year-over-year, from $1.61M to -$52.8M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s financing cash flow?
- Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s financing cash flow has grown at a -53.0% compound annual growth rate (CAGR), from $115.98M to $12.06M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.